论文部分内容阅读
目的:比较曲普瑞林不同给药方式对子宫腺肌病患者病情控制作用的影响。方法:选择我院2011年3月—2012年1月收治的78例子宫腺肌病患者并随机分为2组,对照组38例采用常规给药方式治疗,每4周肌内注射曲普瑞林1次,观察组40例延长给药时间,每6周肌内注射曲普瑞林1次,2组疗程均为24周,比较2组患者病情控制情况。结果:治疗后2组患者的痛经评分明显优于治疗前,月经量均较治疗前明显减少,子宫内膜厚度较治疗前明显变薄,差异均有统计学意义(P<0.05),但2组间差异无统计学意义(P>0.05);治疗后2组患者的黄体生成素(LH)、卵泡刺激素(FSH)及雌二醇(E2)水平均明显降低,与治疗前比较差异均有统计学意义(P<0.05),但2组间差异无统计学意义(P>0.05);2组均无严重不良反应发生。结论:曲普瑞林不同给药方式对子宫腺肌病患者均能起到良好的病情控制作用,且安全性好,但延长给药时间可以减少用药次数及用药量,是临床首选的治疗方案。
Objective: To compare the effects of different administration modes of triptorelin on the disease control in patients with adenomyosis. Methods: Seventy-eight patients with adenomyosis admitted to our hospital from March 2011 to January 2012 were randomly divided into two groups. In the control group, 38 cases were treated by conventional administration. Triptorelin Lin 1 time, the observation group of 40 patients to extend the administration time, intramuscular injection of triptorelin once every 6 weeks, two courses were 24 weeks, the two groups were compared disease control. Results: After treatment, the scores of dysmenorrhea in two groups were significantly better than those before treatment, and the amount of menstrual flow was significantly decreased compared with that before treatment. The thickness of endometrium was significantly thinner than that before treatment, with significant difference (P <0.05) There was no significant difference between the two groups (P> 0.05). After treatment, the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and estradiol (E2) (P <0.05), but there was no significant difference between the two groups (P> 0.05). No serious adverse reactions occurred in the two groups. CONCLUSIONS: Triptorelin administration can play a good role in the control of patients with adenomyosis, and its safety is good. However, prolonged administration can reduce the number and dosage of drugs, which is the first choice of clinical treatment .